ClinicalTrials.gg
CompletedNCT01954394ODYSSEY OLEUpdated Jul 24, 2018Results posted

Open Label Study of Long Term Safety Evaluation of Alirocumab

A Phase 3 interventional study of Alirocumab and Lipid-Modifying Therapy (LMT) in Hypercholesterolemia, sponsored by Sanofi. Completed at 177 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-07-24.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
986
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.

Enrollment
5th of 43
986 · median 107
Started
2013
with 5 others
Phase 3
20 of 43
none open now
Registered
24th of 43
by date
Lead sponsor
28 of 43
Sanofi

Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 5th largest by enrollment, is one of 6 that started in 2013, is one of 20 in phase 3, and was the 24th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About alirocumab

alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing alirocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

Primary Objective:

To assess the long-term safety of alirocumab (SAR236553/REGN727) when added to lipid-lowering therapy in participants with heterozygous familial hypercholesterolemia (heFH) who had completed EFC12492 (NCT01623115), R727-CL-1112 (NCT01709500), EFC12732 (NCT01617655) and LTS11717 (NCT01507831).

Secondary Objectives:

  • To evaluate the long-term efficacy of alirocumab on lipid parameters.
  • To evaluate the long-term immunogenicity of alirocumab.
Read the detailed description

The maximum study duration will be 176 weeks per participant.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants with heFH who had completed one of the four parent studies (EFC12492, R727-CL-1112, EFC12732 and LTS11717).

Exclusion criteria

Exclusion criteria:

Significant protocol deviation in the parent study; Any permanent treatment discontinuation from the parent study.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
986 participants (actual)

Study arms

  • Experimental
    Alirocumab 75 or 150 mg Q2W

    Alirocumab 75 mg or 150 mg every 2 weeks (Q2W) added to stable lipid-modifying therapy (LMT) for up to 168 additional weeks (or until the product was commercially available) in participants who completed the parent studies EFC12492, R727-CL-1112, EFC12732 and LTS11717.

    Drug: Alirocumab · Drug: Lipid-Modifying Therapy (LMT)

Interventions

  • Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.

    Also known as: SAR236553, REGN727, Praluent

  • Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Experienced Adverse Events (AEs)

    Reported AEs are treatment-emergent AEs that is AEs that developed/worsened during the 'treatment-emergent period' (the time from the first dose of alirocumab in this study up to the last dose of alirocumab received in this study +70 days). Clinically significant lab and vital sign abnormalities were to be reported as AEs.

    Time frame: Up to 10 weeks after last study drug administration (maximum of 176 weeks)

Secondary outcomes

  1. Percent Change From Baseline in Calculated LDL-C at Weeks 8, 24, 48, 72, 96, 120, 144 and 168

    Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.

    Time frame: Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168

  2. Absolute Change From Baseline in Calculated LDL-C (mg/dL) at Weeks 8, 24, 48, 72, 96, 120, 144 and 168

    Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.

    Time frame: Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168

  3. Absolute Change From Baseline in Calculated LDL-C (mmol/L) at Weeks 8, 24, 48, 72, 96, 120, 144 and 168

    Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.

    Time frame: Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168

  4. Percentage of Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) Over Time

    Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.

    Time frame: Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168

  5. Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) Over Time

    Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.

    Time frame: Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168

  6. Percentage of Participants With Calculated LDL-C <70 mg/dL (1.81mmol/L) and/or >=50% Reduction in Calculated LDL-C From Baseline (if Calculated LDL-C >=70 mg/dL [1.81mmol/L]) Over Time

    Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.

    Time frame: Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168

  7. Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Weeks 8, 24, 48, 72, 96, 120, 144 and 168

    Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.

    Time frame: Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168

  8. Percent Change From Baseline in Total-cholesterol at Weeks 8, 24, 48, 72, 96, 120, 144 and 168

    Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.

    Time frame: Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168

  9. Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Weeks 8, 24, 48, 72, 96, 120, 144 and 168

    Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.

    Time frame: Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168

  10. Percent Change From Baseline in Fasting Triglycerides (TGs) at Weeks 8, 24, 48, 72, 96, 120, 144 and 168

    Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.

    Time frame: Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168

  11. Percent Change From Baseline in Lipoprotein (a) at Weeks 48, 96, 144 and 168

    Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.

    Time frame: Parent Baseline, Weeks 48, 96, 144, and 168

  12. Percent Change From Baseline in Apolipoprotein-B (Apo-B) at Weeks 48, 96, 144, and 168

    Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.

    Time frame: Parent Baseline, Weeks 48, 96, 144, and 168

  13. Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Weeks 48, 96, 144, and 168

    Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.

    Time frame: Parent Baseline, Weeks 48, 96, 144, and 168

  14. Absolute Change From Baseline in Apo B/Apo A-1 Ratio at Weeks 48, 96, 144, and 168

    Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.

    Time frame: Parent Baseline, Weeks 48, 96, 144, and 168

07

Results

Posted Jul 24, 2018

Participant flow

The study was conducted at 177 centers in 24 countries. Overall, 986 participants who completed study EFC12492 (NCT01623115), R727-CL-1112 (NCT01709500), EFC12732 (NCT01617655) and LTS11717 (NCT01507831) were enrolled between December 2013 and December 2014.

Participant flow — Overall Study
MilestonePlacebo to Alirocumab 75 or 150 mg Q2WAlirocumab to Alirocumab 75 or 150 mg Q2W
Started331655
Treated330655
Completed301598
Not completed3057
Withdrew: Enrolled but not treated10
Withdrew: Adverse event1023
Withdrew: Poor compliance to protocol77
Withdrew: Participant moved04
Withdrew: Related to study drug administration22
Withdrew: Other than specified above1021

Outcome measures

PrimaryPercentage of Participants Who Experienced Adverse Events (AEs)

Reported AEs are treatment-emergent AEs that is AEs that developed/worsened during the 'treatment-emergent period' (the time from the first dose of alirocumab in this study up to the last dose of alirocumab received in this study +70 days). Clinically significant lab and vital sign abnormalities were to be reported as AEs.

Time frame:
Up to 10 weeks after last study drug administration (maximum of 176 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Adverse Events (AEs)
percentage of participantsPlacebo to Alirocumab 75 or 150 mg Q2WAlirocumab to Alirocumab 75 or 150 mg Q2WAlirocumab: All Participants
Any AE83.987.386.2
Any Serious AE20.622.021.5
Any AE leading to treatment discontinuation3.03.53.4
SecondaryPercent Change From Baseline in Calculated LDL-C at Weeks 8, 24, 48, 72, 96, 120, 144 and 168

Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.

Time frame:
Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168
Reported as:
Mean · percent change
Percent Change From Baseline in Calculated LDL-C at Weeks 8, 24, 48, 72, 96, 120, 144 and 168
percent changePlacebo to Alirocumab 75 or 150 mg Q2WAlirocumab to Alirocumab 75 or 150 mg Q2WAlirocumab: All Participants
Week 8-44.9 ± 25.9-43.8 ± 28.7-44.2 ± 27.8
Week 24-46.9 ± 27.5-46.9 ± 29.3-46.9 ± 28.7
Week 48-45.6 ± 28.0-47.5 ± 28.8-46.9 ± 28.6
Week 72-47.7 ± 23.5-47.3 ± 28.4-47.4 ± 26.8
Week 96-47.4 ± 23.8-48.2 ± 28.2-47.9 ± 26.8
Week 120-47.4 ± 24.0-46.6 ± 31.1-46.8 ± 28.8
Week 144-46.5 ± 25.8-49.6 ± 24.6-48.5 ± 25.0
Week 168-43.6 ± 13.4-52.2 ± 20.7-48.8 ± 17.8
SecondaryAbsolute Change From Baseline in Calculated LDL-C (mg/dL) at Weeks 8, 24, 48, 72, 96, 120, 144 and 168

Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.

Time frame:
Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168
Reported as:
Mean · mg/dL
Absolute Change From Baseline in Calculated LDL-C (mg/dL) at Weeks 8, 24, 48, 72, 96, 120, 144 and 168
mg/dLPlacebo to Alirocumab 75 or 150 mg Q2WAlirocumab to Alirocumab 75 or 150 mg Q2WAlirocumab: All Participants
Week 8-66.8 ± 45.6-67.1 ± 49.2-67.0 ± 48.0
Week 24-70.3 ± 49.5-72.7 ± 52.4-71.9 ± 51.4
Week 48-67.8 ± 49.7-73.9 ± 54.3-71.9 ± 52.8
Week 72-71.2 ± 44.5-74.9 ± 54.5-73.7 ± 51.4
Week 96-70.2 ± 45.9-75.9 ± 55.0-74.0 ± 52.2
Week 120-72.3 ± 45.6-75.2 ± 59.7-74.2 ± 55.2
Week 144-73.1 ± 50.0-86.2 ± 57.8-81.6 ± 55.4
Week 168-66.1 ± 24.7-99.4 ± 48.3-86.1 ± 42.4
SecondaryAbsolute Change From Baseline in Calculated LDL-C (mmol/L) at Weeks 8, 24, 48, 72, 96, 120, 144 and 168

Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.

Time frame:
Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168
Reported as:
Mean · mmol/L
Absolute Change From Baseline in Calculated LDL-C (mmol/L) at Weeks 8, 24, 48, 72, 96, 120, 144 and 168
mmol/LPlacebo to Alirocumab 75 or 150 mg Q2WAlirocumab to Alirocumab 75 or 150 mg Q2WAlirocumab: All Participants
Week 8-1.729 ± 1.180-1.738 ± 1.273-1.735 ± 1.242
Week 24-1.821 ± 1.282-1.883 ± 1.356-1.863 ± 1.332
Week 48-1.757 ± 1.286-1.914 ± 1.405-1.861 ± 1.368
Week 72-1.843 ± 1.154-1.940 ± 1.411-1.908 ± 1.332
Week 96-1.818 ± 1.190-1.965 ± 1.426-1.916 ± 1.353
Week 120-1.874 ± 1.180-1.949 ± 1.546-1.923 ± 1.428
Week 144-1.894 ± 1.294-2.232 ± 1.498-2.114 ± 1.436
Week 168-1.712 ± 0.641-2.574 ± 1.252-2.229 ± 1.098
SecondaryPercentage of Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) Over Time

Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.

Time frame:
Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168
Reported as:
Number · percentage of participants
Percentage of Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) Over Time
percentage of participantsPlacebo to Alirocumab 75 or 150 mg Q2WAlirocumab to Alirocumab 75 or 150 mg Q2WAlirocumab: All Participants
Baseline12.111.511.7
Week 871.086.181.1
Week 2477.075.776.1
Week 4877.776.476.8
Week 7282.977.679.4
Week 9679.276.877.6
Week 12078.276.777.2
Week 14472.574.473.7
Week 16875.083.380.0
SecondaryPercentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) Over Time

Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.

Time frame:
Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168
Reported as:
Number · percentage of participants
Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) Over Time
percentage of participantsPlacebo to Alirocumab 75 or 150 mg Q2WAlirocumab to Alirocumab 75 or 150 mg Q2WAlirocumab: All Participants
Baseline0.91.21.1
Week 847.466.460.1
Week 2453.453.153.2
Week 4851.153.552.7
Week 7257.053.254.5
Week 9653.056.455.3
Week 12052.750.951.5
Week 14446.448.147.5
Week 16850.033.340.0
SecondaryPercentage of Participants With Calculated LDL-C <70 mg/dL (1.81mmol/L) and/or >=50% Reduction in Calculated LDL-C From Baseline (if Calculated LDL-C >=70 mg/dL [1.81mmol/L]) Over Time

Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.

Time frame:
Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168
Reported as:
Number · percentage of participants
Percentage of Participants With Calculated LDL-C <70 mg/dL (1.81mmol/L) and/or >=50% Reduction in Calculated LDL-C From Baseline (if Calculated LDL-C >=70 mg/dL [1.81mmol/L]) Over Time
percentage of participantsPlacebo to Alirocumab 75 or 150 mg Q2WAlirocumab to Alirocumab 75 or 150 mg Q2WAlirocumab: All Participants
Baseline0.91.21.1
Week 849.567.161.3
Week 2454.154.354.2
Week 4852.154.553.7
Week 7257.354.455.4
Week 9653.057.756.1
Week 12053.253.153.1
Week 14446.448.848.0
Week 16850.033.340.0
SecondaryPercent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Weeks 8, 24, 48, 72, 96, 120, 144 and 168

Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.

Time frame:
Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168
Reported as:
Mean · percent change
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Weeks 8, 24, 48, 72, 96, 120, 144 and 168
percent changePlacebo to Alirocumab 75 or 150 mg Q2WAlirocumab to Alirocumab 75 or 150 mg Q2WAlirocumab: All Participants
Week 8-38.1 ± 24.8-37.6 ± 26.6-37.8 ± 26.0
Week 24-40.6 ± 25.5-40.4 ± 27.9-40.5 ± 27.1
Week 48-39.7 ± 25.5-40.6 ± 27.6-40.3 ± 26.9
Week 72-40.8 ± 22.6-40.3 ± 26.5-40.5 ± 25.3
Week 96-39.9 ± 23.5-40.5 ± 26.6-40.3 ± 25.6
Week 120-41.4 ± 22.1-38.4 ± 29.7-39.5 ± 27.3
Week 144-39.8 ± 22.9-41.8 ± 24.0-41.1 ± 23.6
Week 168-40.7 ± 12.3-47.7 ± 18.8-44.9 ± 16.1
SecondaryPercent Change From Baseline in Total-cholesterol at Weeks 8, 24, 48, 72, 96, 120, 144 and 168

Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.

Time frame:
Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168
Reported as:
Mean · percent change
Percent Change From Baseline in Total-cholesterol at Weeks 8, 24, 48, 72, 96, 120, 144 and 168
percent changePlacebo to Alirocumab 75 or 150 mg Q2WAlirocumab to Alirocumab 75 or 150 mg Q2WAlirocumab: All Participants
Week 8-27.9 ± 19.3-27.7 ± 20.7-27.7 ± 20.2
Week 24-30.1 ± 20.3-30.2 ± 21.6-30.1 ± 21.2
Week 48-29.0 ± 20.5-30.0 ± 21.6-29.7 ± 21.2
Week 72-29.9 ± 18.0-30.1 ± 20.8-30.0 ± 19.9
Week 96-28.9 ± 18.3-29.9 ± 21.1-29.6 ± 20.2
Week 120-30.2 ± 17.2-28.4 ± 22.8-29.0 ± 21.0
Week 144-29.1 ± 18.2-31.3 ± 19.1-30.5 ± 18.8
Week 168-32.3 ± 12.4-39.1 ± 14.3-36.4 ± 13.3
SecondaryPercent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Weeks 8, 24, 48, 72, 96, 120, 144 and 168

Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.

Time frame:
Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168
Reported as:
Mean · percent change
Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Weeks 8, 24, 48, 72, 96, 120, 144 and 168
percent changePlacebo to Alirocumab 75 or 150 mg Q2WAlirocumab to Alirocumab 75 or 150 mg Q2WAlirocumab: All Participants
Week 85.6 ± 17.16.6 ± 17.36.3 ± 17.3
Week 245.7 ± 17.45.8 ± 16.95.8 ± 17.1
Week 487.1 ± 17.87.2 ± 19.27.2 ± 18.7
Week 726.7 ± 17.67.2 ± 19.97.0 ± 19.1
Week 967.2 ± 18.87.2 ± 18.77.2 ± 18.7
Week 1208.0 ± 18.48.1 ± 18.78.1 ± 18.6
Week 1448.8 ± 19.28.8 ± 24.88.8 ± 23.0
Week 168-6.6 ± 26.2-0.3 ± 9.9-2.8 ± 17.1
SecondaryPercent Change From Baseline in Fasting Triglycerides (TGs) at Weeks 8, 24, 48, 72, 96, 120, 144 and 168

Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.

Time frame:
Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168
Reported as:
Mean · percent change
Percent Change From Baseline in Fasting Triglycerides (TGs) at Weeks 8, 24, 48, 72, 96, 120, 144 and 168
percent changePlacebo to Alirocumab 75 or 150 mg Q2WAlirocumab to Alirocumab 75 or 150 mg Q2WAlirocumab: All Participants
Week 83.4 ± 40.53.5 ± 47.03.5 ± 44.9
Week 240.6 ± 39.91.0 ± 45.90.9 ± 44.0
Week 480.8 ± 37.55.1 ± 78.03.7 ± 67.2
Week 724.3 ± 43.33.6 ± 42.93.8 ± 43.0
Week 969.1 ± 53.29.3 ± 55.29.2 ± 54.5
Week 120-1.2 ± 35.310.8 ± 48.56.7 ± 44.8
Week 1445.0 ± 38.07.7 ± 49.86.8 ± 45.9
Week 168-22.1 ± 21.9-10.3 ± 27.1-15.0 ± 24.6
SecondaryPercent Change From Baseline in Lipoprotein (a) at Weeks 48, 96, 144 and 168

Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.

Time frame:
Parent Baseline, Weeks 48, 96, 144, and 168
Reported as:
Mean · percent change
Percent Change From Baseline in Lipoprotein (a) at Weeks 48, 96, 144 and 168
percent changePlacebo to Alirocumab 75 or 150 mg Q2WAlirocumab to Alirocumab 75 or 150 mg Q2WAlirocumab: All Participants
Week 48-15.0 ± 158.4-26.4 ± 40.2-22.6 ± 97.6
Week 96-13.9 ± 171.7-21.4 ± 132.7-18.9 ± 146.9
Week 144-20.1 ± 46.1-33.0 ± 25.0-28.5 ± 34.3
Week 168-30.3 ± 18.2-29.2 ± 15.4-29.6 ± 15.6
SecondaryPercent Change From Baseline in Apolipoprotein-B (Apo-B) at Weeks 48, 96, 144, and 168

Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.

Time frame:
Parent Baseline, Weeks 48, 96, 144, and 168
Reported as:
Mean · percent change
Percent Change From Baseline in Apolipoprotein-B (Apo-B) at Weeks 48, 96, 144, and 168
percent changePlacebo to Alirocumab 75 or 150 mg Q2WAlirocumab to Alirocumab 75 or 150 mg Q2WAlirocumab: All Participants
Week 48-36.9 ± 21.7-37.8 ± 23.4-37.5 ± 22.9
Week 96-36.9 ± 20.9-38.0 ± 22.9-37.6 ± 22.3
Week 144-33.9 ± 20.9-36.9 ± 21.3-35.9 ± 21.2
Week 168-38.0 ± 9.0-43.1 ± 20.7-41.1 ± 16.5
SecondaryPercent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Weeks 48, 96, 144, and 168

Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.

Time frame:
Parent Baseline, Weeks 48, 96, 144, and 168
Reported as:
Mean · percent change
Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Weeks 48, 96, 144, and 168
percent changePlacebo to Alirocumab 75 or 150 mg Q2WAlirocumab to Alirocumab 75 or 150 mg Q2WAlirocumab: All Participants
Week 485.6 ± 14.55.8 ± 17.25.7 ± 16.3
Week 967.8 ± 15.48.5 ± 14.18.3 ± 14.5
Week 14411.2 ± 16.310.2 ± 18.710.6 ± 17.8
Week 1680.9 ± 19.33.9 ± 9.32.7 ± 13.2
SecondaryAbsolute Change From Baseline in Apo B/Apo A-1 Ratio at Weeks 48, 96, 144, and 168

Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.

Time frame:
Parent Baseline, Weeks 48, 96, 144, and 168
Reported as:
Mean · ratio
Absolute Change From Baseline in Apo B/Apo A-1 Ratio at Weeks 48, 96, 144, and 168
ratioPlacebo to Alirocumab 75 or 150 mg Q2WAlirocumab to Alirocumab 75 or 150 mg Q2WAlirocumab: All Participants
Week 48-0.340 ± 0.245-0.361 ± 0.304-0.354 ± 0.286
Week 96-0.340 ± 0.228-0.375 ± 0.268-0.363 ± 0.256
Week 144-0.342 ± 0.242-0.414 ± 0.433-0.389 ± 0.379
Week 168-0.370 ± 0.161-0.498 ± 0.280-0.447 ± 0.238

Adverse events

Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Week 176 post-treatment follow-up visit) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo to Alirocumab 75 or 150 mg Q2W4/330 (1.2%)68/330 (20.6%)183/330 (55.5%)
Alirocumab to Alirocumab 75 or 150 mg Q2W7/655 (1.1%)144/655 (22%)366/655 (55.9%)
Alirocumab: All Participants11/985 (1.1%)212/985 (21.5%)549/985 (55.7%)
Most frequent serious events
Showing 10 of 242
Most frequent serious events
EventPlacebo to Alirocumab 75 or 150 mg Q2WAlirocumab to Alirocumab 75 or 150 mg Q2WAlirocumab: All Participants
Angina pectorisCardiac disorders6/3308/65514/985
Angina unstableCardiac disorders4/3305/6559/985
SyncopeNervous system disorders1/3306/6557/985
Transient ischaemic attackNervous system disorders0/3306/6556/985
Coronary artery stenosisCardiac disorders3/3303/6556/985
Cardiac failure congestiveCardiac disorders3/3301/6554/985
OsteoarthritisMusculoskeletal and connective tissue disorders2/3305/6557/985
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/3305/6556/985
Acute myocardial infarctionCardiac disorders2/3304/6556/985
Coronary artery diseaseCardiac disorders2/3304/6556/985
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPlacebo to Alirocumab 75 or 150 mg Q2WAlirocumab to Alirocumab 75 or 150 mg Q2WAlirocumab: All Participants
Viral upper respiratory tract infectionInfections and infestations51/33093/655144/985
Upper respiratory tract infectionInfections and infestations31/33071/655102/985
InfluenzaInfections and infestations34/33061/65595/985
ArthralgiaMusculoskeletal and connective tissue disorders34/33053/65587/985
Back painMusculoskeletal and connective tissue disorders26/33056/65582/985
Injection site reactionGeneral disorders26/33028/65554/985
MyalgiaMusculoskeletal and connective tissue disorders15/33044/65559/985
DiarrhoeaGastrointestinal disorders19/33043/65562/985
Urinary tract infectionInfections and infestations21/33028/65549/985
BronchitisInfections and infestations19/33041/65560/985

Baseline characteristics

All enrolled participants who received at least one dose or part of a dose of alirocumab in this study. Participant who was not treated, was not included in any analysis.

Age, Continuous
Age, Continuous(years)Placebo to Alirocumab 75 or 150 mg Q2WAlirocumab to Alirocumab 75 or 150 mg Q2WTotal
Mean54.8 ± 11.454.1 ± 12.154.4 ± 11.9
Sex: Female, Male
Sex: Female, Male(Participants)Placebo to Alirocumab 75 or 150 mg Q2WAlirocumab to Alirocumab 75 or 150 mg Q2WTotal
Female148287435
Male182368550
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo to Alirocumab 75 or 150 mg Q2WAlirocumab to Alirocumab 75 or 150 mg Q2WTotal
Hispanic or Latino122739
Not Hispanic or Latino317623940
Unknown or Not Reported156
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo to Alirocumab 75 or 150 mg Q2WAlirocumab to Alirocumab 75 or 150 mg Q2WTotal
White310628938
Black or African American224
Asian268
American Indian or Alaska Native123
Native Hawaiian or Other Pacific Islander101
Other4711
White/Black or African American6511
White/Asian257
White/American Indian or Alaska Native101
Black or African American/Asian101
Calculated LDL-C in mg/dL
Calculated LDL-C in mg/dL(mg/dL)Placebo to Alirocumab 75 or 150 mg Q2WAlirocumab to Alirocumab 75 or 150 mg Q2WTotal
Mean148.8 ± 48.8153.5 ± 55.3152.0 ± 53.2
Calculated LDL-C in mmol/L
Calculated LDL-C in mmol/L(mmol/L)Placebo to Alirocumab 75 or 150 mg Q2WAlirocumab to Alirocumab 75 or 150 mg Q2WTotal
Mean3.854 ± 1.2653.977 ± 1.4323.936 ± 1.379
08

Study locations

177 sites
  • Investigational Site Number 840321
    Huntsville, Alabama 35801, United States
  • Investigational Site Number 840341
    Tempe, Arizona 85282, United States
  • Investigational Site Number 840334
    Bell Gardens, California 90201, United States
  • Investigational Site Number 840319
    Fountain Valley, California 92708, United States
  • Investigational Site Number 840336
    Los Angeles, California 90048, United States
  • Investigational Site Number 840339
    Mission Viejo, California 92691, United States
  • Investigational Site Number 840337
    Newport Beach, California 92663, United States
  • Investigational Site Number 840306
    Golden, Colorado 80401, United States
  • Investigational Site Number 840328
    Washington, District of Columbia 20037, United States
  • Investigational Site Number 840344
    Atlantis, Florida 33462, United States
  • Investigational Site Number 840353
    Clearwater, Florida 33756, United States
  • Investigational Site Number 840318
    Fort Lauderdale, Florida 33308-4311, United States
  • Investigational Site Number 840327
    Jacksonville, Florida 32216, United States
  • Investigational Site Number 840309
    Miami, Florida 33174, United States
  • Investigational Site Number 840351
    Sarasota, Florida 34239, United States
  • Investigational Site Number 840315
    Evanston, Illinois 60201, United States
  • Investigational Site Number 840305
    Oakbrook Terrace, Illinois 60181, United States
  • Investigational Site Number 840333
    Iowa City, Iowa 52242, United States
  • Investigational Site Number 840329
    Kansas City, Kansas 66160, United States
  • Investigational Site Number 840345
    Auburn, Maine 04210, United States
  • Investigational Site Number 840338
    Biddeford, Maine 04005, United States
  • Investigational Site Number 840322
    Boston, Massachusetts 02114, United States
  • Investigational Site Number 840346
    Framingham, Massachusetts 01702, United States
  • Investigational Site Number 840317
    Saint Louis, Missouri 63110, United States
  • Investigational Site Number 840349
    Saint Louis, Missouri 63136, United States
  • Investigational Site Number 840314
    Morristown, New Jersey 07901, United States
  • Investigational Site Number 840316
    New York, New York 10032, United States
  • Investigational Site Number 840324
    Poughkeepsie, New York 12601, United States
  • Investigational Site Number 840303
    Charlotte, North Carolina 28204, United States
  • Investigational Site Number 840320
    Durham, North Carolina 27710, United States
  • Investigational Site Number 840348
    Raleigh, North Carolina 27609, United States
  • Investigational Site Number 840340
    Cincinnati, Ohio 45227, United States
  • Investigational Site Number 840302
    Marion, Ohio 43302, United States
  • Investigational Site Number 840330
    Portland, Oregon 97239, United States
  • Investigational Site Number 840352
    Beaver, Pennsylvania 15009, United States
  • Investigational Site Number 840308
    Philadelphia, Pennsylvania 19104, United States
  • Investigational Site Number 840342
    Scranton, Pennsylvania 18503, United States
  • Investigational Site Number 840304
    Summerville, South Carolina 29485, United States
  • Investigational Site Number 840311
    Dallas, Texas 75216, United States
  • Investigational Site Number 840312
    Dallas, Texas 75226, United States
  • Investigational Site Number 840301
    Fort Worth, Texas 76104, United States
  • Investigational Site Number 840343
    Bountiful, Utah 84010, United States
  • Investigational Site Number 840354
    Chesapeake, Virginia 23320, United States
  • Investigational Site Number 840350
    Spokane, Washington 99204, United States
  • Investigational Site Number 032302
    Caba, C1119ACN, Argentina
  • Investigational Site Number 032301
    Coronel Suarez, B7540GHD, Argentina
  • Investigational Site Number 040302
    Graz, 8036, Austria
  • Investigational Site Number 040303
    Sankt Stefan, 8511, Austria
  • Investigational Site Number 040301
    Wien, 1130, Austria
  • Investigational Site Number 056301
    Natoye, 5360, Belgium
  • Investigational Site Number 100302
    Sofia, 1233, Bulgaria
  • Investigational Site Number 100301
    Sofia, 1527, Bulgaria
  • Investigational Site Number 124303
    Chicoutimi, G7H 7K9, Canada
  • Investigational Site Number 124302
    Montreal, H1W 2R7, Canada
  • Investigational Site Number 124301
    Quebec, G1V 4W2, Canada
  • Investigational Site Number 124306
    Sherbrooke, J1H 5N4, Canada
  • Investigational Site Number 124305
    Toronto, M5C 2T2, Canada
  • Investigational Site Number 124304
    Victoria, V8T 5G4, Canada
  • Investigational Site Number 203307
    Hradec Kralove, 500 05, Czechia
  • Investigational Site Number 203305
    Praha 2, 12808, Czechia
  • Investigational Site Number 203301
    Praha 4, 14021, Czechia
  • Investigational Site Number 203306
    Praha 5 - Motol, 15006, Czechia
  • Investigational Site Number 203303
    Praha 8, 180 81, Czechia
  • Investigational Site Number 203309
    Trutnov, 54121, Czechia
  • Investigational Site Number 203304
    Uherske Hradiste, 68601, Czechia
  • Investigational Site Number 203302
    Zlin, 76275, Czechia
  • Investigational Site Number 208301
    Aalborg, 9000, Denmark
  • Investigational Site Number 208306
    Aarhus, 8200, Denmark
  • Investigational Site Number 208302
    Esbjerg, 6700, Denmark
  • Investigational Site Number 208303
    Roskilde, 4000, Denmark
  • Investigational Site Number 208304
    Svendborg, 5700, Denmark
  • Investigational Site Number 246302
    Joensuu, 80100, Finland
  • Investigational Site Number 246301
    Kokkola, 67100, Finland
  • Investigational Site Number 246304
    Vantaa, 01600, Finland
  • Investigational Site Number 250303
    Dijon, 21000, France
  • Investigational Site Number 250304
    Lille Cedex, 59037, France
  • Investigational Site Number 250302
    Nantes, 44093, France
  • Investigational Site Number 250301
    Paris, 75013, France
  • Investigational Site Number 250305
    Pessac, 33604, France
  • Investigational Site Number 250306
    Rennes, 35033, France
  • Investigational Site Number 276302
    Berlin, 10117, Germany
  • Investigational Site Number 276305
    Frankfurt A.M., 60596, Germany
  • Investigational Site Number 276306
    Leipzig, 04103, Germany
  • Investigational Site Number 276301
    Magdeburg, 39120, Germany
  • Investigational Site Number 276307
    Witten, 58455, Germany
  • Investigational Site Number 348301
    Baja, 6500, Hungary
  • Investigational Site Number 376302
    Holon, 58100, Israel
  • Investigational Site Number 376304
    Jerusalem, 91120, Israel
  • Investigational Site Number 376303
    Safed, 13110, Israel
  • Investigational Site Number 376301
    Tel Hashomer, 52621, Israel
  • Investigational Site Number 380302
    Chieti, 66100, Italy
  • Investigational Site Number 380304
    Milano, 20138, Italy
  • Investigational Site Number 380303
    Napoli, 80131, Italy
  • Investigational Site Number 380301
    Palermo, 90127, Italy
  • Investigational Site Number 484301
    Mexico, 03300, Mexico
  • Investigational Site Number 528317
    Alkmaar, 1815 JD, Netherlands
  • Investigational Site Number 528301
    Amsterdam-Zuidoost, 1105 AZ, Netherlands
  • Investigational Site Number 528320
    Apeldoorn, 7314 ET, Netherlands
  • Investigational Site Number 528309
    Delfzijl, 9934 JD, Netherlands
  • Investigational Site Number 528313
    Eindhoven, 5616GB, Netherlands

Showing the first 100 of 177 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Dufour R, Hovingh GK, Guyton JR, Langslet G, Baccara-Dinet MT, Din-Bell C, Manvelian G, Farnier M. Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial. J Clin Lipidol. 2019 Jan-Feb;13(1):138-147. doi: 10.1016/j.jacl.2018.11.007. Epub 2018 Nov 30. PubMed 30591415 ↗
  • Farnier M, Hovingh GK, Langslet G, Dufour R, Baccara-Dinet MT, Din-Bell C, Manvelian G, Guyton JR. Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program. Atherosclerosis. 2018 Nov;278:307-314. doi: 10.1016/j.atherosclerosis.2018.08.036. Epub 2018 Sep 1. PubMed 30293878 ↗
  • Hovingh GK, Guyton JR, Langslet G, Dufour R, Baccara-Dinet MT, Din-Bell C, Manvelian G, Farnier M. Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia. J Clin Lipidol. 2018 Nov-Dec;12(6):1463-1470. doi: 10.1016/j.jacl.2018.08.011. Epub 2018 Aug 30. PubMed 30287210 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of Jun 2017 and a completion of Jun 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2018, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2013
First posted
Oct 1, 2013
Start
Dec 17, 2013
Primary completionActual
Jun 30, 2017
CompletionActual
Jun 30, 2017
Results first posted
Jul 24, 2018
Last update
Jul 24, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01954394
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Oct 1, 2013
Start date
Dec 17, 2013
Primary completion
Jun 30, 2017
Completion
Jun 30, 2017
Results posted
Jul 24, 2018
Last update
Jul 24, 2018

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alirocumab

Start the discussion